FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3205018834> ?p ?o ?g. }

• W3205018834 endingPage "2568" @default.
• W3205018834 startingPage "2566" @default.
• W3205018834 abstract "In their new article in the Journal of Investigative Dermatology, Tseng et al. (2021) confirm that the sensitivity of melanoma cells to anti‒PD-L1 checkpoint inhibitor therapy is correlated with high PD-L1 surface expression. By blocking PD-L1 membrane clearing, controlled by LRP1 and PAI-1, the expression of high-cell-surface levels of PD-L1 was maintained. In their new article in the Journal of Investigative Dermatology, Tseng et al. (2021) confirm that the sensitivity of melanoma cells to anti‒PD-L1 checkpoint inhibitor therapy is correlated with high PD-L1 surface expression. By blocking PD-L1 membrane clearing, controlled by LRP1 and PAI-1, the expression of high-cell-surface levels of PD-L1 was maintained. Immune checkpoint inhibitors (ICIs) have changed the landscape of cancer treatment. In particular, the PD-1 and PD-L1 immune checkpoint molecules are significantly involved in the evasion of tumors from immune control, and the use of anti‒PD-L1 mAbs has revolutionized the treatment of various types of cancer, including melanoma. However, despite initial enthusiasm, several clinical trials have shown that although treatment with anti‒PD-L1 mAbs in advanced melanoma showed higher, more durable responses in a subset of patients, there was no difference between survival and that observed when conventional chemotherapy was used (Wang et al., 2017Wang D.Y. Eroglu Z. Ozgun A. Leger P.D. Zhao S. Ye F. et al.Clinical features of acquired resistance to anti-PD-1 therapy in advanced melanoma.Cancer Immunol Res. 2017; 5: 357-362Crossref PubMed Scopus (23) Google Scholar). In their new article in the Journal of Investigative Dermatology, Tseng et al., 2021Tseng Y.-J. Lee C.-H. Chen W.-Y. Yang J.-L. Tzeng H.-T. Inhibition of PAI-1 blocks PD-L1 endocytosis and improves the response of melanoma cells to immune checkpoint blockade.J Invest Dermatol. 2021; 141: 2690-2698.e6Google Scholar show that targeting extracellular PAI-1 through the PAI-1 inhibitor tiplaxtinin (TPX) synergizes with anti‒PD-L1 checkpoint blockade in a model of murine melanoma, thus paving the way for potentially more effective melanoma treatment. This work stems from two different lines of previous investigations indicating that improved clinical outcomes in patients with melanoma subjected to anti‒PD-L1 therapy are associated with high PD-L1 positivity (Patel and Kurzrock, 2015Patel S.P. Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy.Mol Cancer Ther. 2015; 14: 847-856Crossref PubMed Scopus (1206) Google Scholar) and that a temporary inhibition of PD-L1 and EGFR‒clathrin‒mediated endocytosis potentiated the response of human tumors to ICIs (Chew et al., 2020Chew H.Y. De Lima P.O. Gonzalez Cruz J.L. Banushi B. Echejoh G. Hu L. et al.Endocytosis inhibition in humans to improve responses to ADCC-mediating antibodies.Cell. 2020; 180: 895-914.e27Abstract Full Text Full Text PDF PubMed Scopus (43) Google Scholar). As reported in this article, using immunohistochemical analysis of a significant number of paraffin-embedded sections from patients with melanoma, Tseng et al., 2021Tseng Y.-J. Lee C.-H. Chen W.-Y. Yang J.-L. Tzeng H.-T. Inhibition of PAI-1 blocks PD-L1 endocytosis and improves the response of melanoma cells to immune checkpoint blockade.J Invest Dermatol. 2021; 141: 2690-2698.e6Google Scholar showed that individuals with low PAI-1 expression and high levels of PD-L1 were associated with early melanoma stages (stages I and II), whereas high PAI-1/PD-L1 ratios were associated with late stages (stages III and IV), supporting the data obtained in vitro and in animals.Clinical Implications•High-grade melanomas exhibit lower surface expression of PD-L1.•There is an inverse relationship between PAI-1 levels and anti‒PD-L1 efficacy in patients with melanoma.•PAI-1 blockade could enhance the efficacy of anti‒PD-L1 therapy in patients with melanoma. •High-grade melanomas exhibit lower surface expression of PD-L1.•There is an inverse relationship between PAI-1 levels and anti‒PD-L1 efficacy in patients with melanoma.•PAI-1 blockade could enhance the efficacy of anti‒PD-L1 therapy in patients with melanoma. Following up on the observation that extracellular PAI-1 promoted the internalization of surface-expressed PD-L1 in melanoma cells by inducing clathrin-mediated endocytosis, Tseng et al., 2021Tseng Y.-J. Lee C.-H. Chen W.-Y. Yang J.-L. Tzeng H.-T. Inhibition of PAI-1 blocks PD-L1 endocytosis and improves the response of melanoma cells to immune checkpoint blockade.J Invest Dermatol. 2021; 141: 2690-2698.e6Google Scholar tested the hypothesis that PD-L1 was translocated to lysosomes by PAI-1‒dependent mechanisms, showing that such transport is mediated by LRP1. LRP1 is a very sociable multipurpose molecule that belongs to the family of receptors for low-density lipoproteins. LRP1 (also known as CD91) interacts with >35 ligands, and it has been identified as the receptor for α2M-proteinase complex and heat shock proteins on antigen-presenting cells (Etique et al., 2013Etique N. Verzeaux L. Dedieu S. Emonard H. LRP-1: a checkpoint for the extracellular matrix proteolysis.Biomed Res Int. 2013; 2013: 152163Crossref PubMed Scopus (58) Google Scholar). LRP1 (Figure 1) is characterized by an extracellular α-chain, which interacts with extracellular matrix proteins, proteases, protease-inhibitor complexes, GFs, and proteins involved in lipid metabolism. The transmembrane β-chain stimulates the endocytosis of molecules linked to the α-chain and activates signaling systems (Etique et al., 2013Etique N. Verzeaux L. Dedieu S. Emonard H. LRP-1: a checkpoint for the extracellular matrix proteolysis.Biomed Res Int. 2013; 2013: 152163Crossref PubMed Scopus (58) Google Scholar). From a general standpoint, LRP1 keeps in check the extent of extracellular proteolysis. In this context, the control of PAI-1 activity plays an important role in the regulation of extracellular fibrinolysis linked to the activity of uPA and tPA. The mechanism is simple (Figure 1): after the interaction of uPA with its cognate receptor uPAR (which is in turn associated with membrane integrins), PAI-1 binds to uPA and neutralizes its proteolytic activity. The complex interacts with both α- and β-chains of LRP1. Notably, each member of the cell-associated fibrinolytic system may interact with LRP1 in the absence of other components with lower affinity. The incorporation of PAI-1 leads to one-order-of-magnitude higher interactions, suggesting that the binding of proteinases to PAI-1 uncovers cryptic binding sites with a high affinity for LRP1 (Kounnas et al., 1993Kounnas M.Z. Henkin J. Argraves W.S. Strickland D.K. Low density lipoprotein-related protein/alpha 2-macroglobulin receptor mediates cellular uptake of pro-urokinase.J Biol Chem. 1993; 268: 21862-21867Abstract Full Text PDF PubMed Google Scholar). Although LRP1 is present in clathrin-coated pits as well as in caveolae (Boucher et al., 2002Boucher P. Liu P. Gotthardt M. Hiesberger T. Anderson R.G. Herz J. Platelet-derived growth factor mediates tyrosine phosphorylation of the cytoplasmic domain of the low density lipoprotein receptor-related protein in caveolae.J Biol Chem. 2002; 277: 15507-15513Abstract Full Text Full Text PDF PubMed Scopus (174) Google Scholar), Tseng et al., 2021Tseng Y.-J. Lee C.-H. Chen W.-Y. Yang J.-L. Tzeng H.-T. Inhibition of PAI-1 blocks PD-L1 endocytosis and improves the response of melanoma cells to immune checkpoint blockade.J Invest Dermatol. 2021; 141: 2690-2698.e6Google Scholar show that the internalization of the LRP1 multimolecular complexes occurs by inducing clathrin-coated pits‒dependent endocytosis when PAI-1 is involved, suggesting a tight coregulation of cell surface PD-L1 that has previously been reported to undergo clathrin- but not caveolin-mediated endocytosis (Li et al., 2018Li C.W. Lim S.O. Chung E.M. Kim Y.S. Park A.H. Yao J. et al.Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1.Cancer Cell. 2018; 33: 187-201.e10Abstract Full Text Full Text PDF PubMed Scopus (214) Google Scholar). The receptors forming part of the internalization complex (LRP1 and uPAR) are recycled to the cell membrane, whereas the ligands (uPA, tPA, PAI-1) are degraded in lysosomes (Etique et al., 2013Etique N. Verzeaux L. Dedieu S. Emonard H. LRP-1: a checkpoint for the extracellular matrix proteolysis.Biomed Res Int. 2013; 2013: 152163Crossref PubMed Scopus (58) Google Scholar), undergoing the same fate as PD-L1 (Figure 1). Tseng et al., 2021Tseng Y.-J. Lee C.-H. Chen W.-Y. Yang J.-L. Tzeng H.-T. Inhibition of PAI-1 blocks PD-L1 endocytosis and improves the response of melanoma cells to immune checkpoint blockade.J Invest Dermatol. 2021; 141: 2690-2698.e6Google Scholar have concluded that coincident with LRP1-mediated endocytosis of PAI-1, PD-L1, which is also associated with clathrin-coated pits, is internalized in endosomal vesicles and is directed to lysosomes for degradation, leading to the decreased expression on the surfaces of melanoma cells and consequent desensitization to therapy with specific PD-L1 inhibitors. Tseng et al., 2021Tseng Y.-J. Lee C.-H. Chen W.-Y. Yang J.-L. Tzeng H.-T. Inhibition of PAI-1 blocks PD-L1 endocytosis and improves the response of melanoma cells to immune checkpoint blockade.J Invest Dermatol. 2021; 141: 2690-2698.e6Google Scholar used various approaches to block endocytosis of the LRP1 receptor complex (and PD-L1)—ranging from inhibiting transport from the endoplasmic reticulum to the Golgi complex to blocking microtubule polymerization or function of the actin filaments—and ultimately chose to study TPX, a low-molecular-weight inhibitor of PAI-1. Although TPX was not promising in clinical trials owing to difficulties in inherent bleeding disorders (Brown, 2010Brown N.J. Therapeutic potential of plasminogen activator inhibitor-1 inhibitors.Ther Adv Cardiovasc Dis. 2010; 4: 315-324Crossref PubMed Scopus (41) Google Scholar), Tseng et al., 2021Tseng Y.-J. Lee C.-H. Chen W.-Y. Yang J.-L. Tzeng H.-T. Inhibition of PAI-1 blocks PD-L1 endocytosis and improves the response of melanoma cells to immune checkpoint blockade.J Invest Dermatol. 2021; 141: 2690-2698.e6Google Scholar successfully used it both in vitro and in vivo in a syngeneic model of melanoma, showing that TPX inhibition of PAI-1‒dependent endocytosis blocks lysosomal degradation of PDL-1, maintains a high surface expression of PDL-1, and enhances the tumor-suppressive activity of anti‒PD-L1 blockade. These results are very encouraging and may pave the way for intensified research on PAI-1 inhibitors with a more favorable benefit-to-risk ratio. As underlined by Tseng et al., 2021Tseng Y.-J. Lee C.-H. Chen W.-Y. Yang J.-L. Tzeng H.-T. Inhibition of PAI-1 blocks PD-L1 endocytosis and improves the response of melanoma cells to immune checkpoint blockade.J Invest Dermatol. 2021; 141: 2690-2698.e6Google Scholar, the pleiotropic properties of PAI-1 extend beyond the inverse relationship with the expression of PD-L1, involving the wider field of the basis of malignancy, particularly the promotion of angiogenesis and the control of tumor invasion and metastasis. Virtually all types of human cancers, including melanoma, are characterized by more or less relevant alterations of the molecules of the membrane-associated fibrinolytic system. Bearing in mind that PAI-1 has been validated as a negative prognostic factor for clinical use in level-of-evidence-1 studies in mammary carcinoma (Duffy et al., 2014Duffy M.J. McGowan P.M. Harbeck N. Thomssen C. Schmitt M. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.Breast Cancer Res. 2014; 16: 428Crossref PubMed Scopus (163) Google Scholar) and that it has been shown to negatively impact the prognosis of patients with melanoma (Tseng et al., 2021Tseng Y.-J. Lee C.-H. Chen W.-Y. Yang J.-L. Tzeng H.-T. Inhibition of PAI-1 blocks PD-L1 endocytosis and improves the response of melanoma cells to immune checkpoint blockade.J Invest Dermatol. 2021; 141: 2690-2698.e6Google Scholar), the discovery of the regulation of PDL-1 expression by inhibition of PAI-1 phagocytosis lays the foundations for the development of new drugs that may have wide-ranging effects on the natural history of human cancers. Mario Del Rosso: https://orcid.org/0000-0002-2980-2731 Gabriella Fibbi: https://orcid.org/0000-0002-0629-851X Anna Laurenzana: https://orcid.org/0000-0002-8745-3808 Francesca Margheri: https://orcid.org/0000-0001-7122-6574 Anastasia Chillà: https://orcid.org/0000-0002-2130-8309 The authors state no conflict of interest. Inhibition of PAI-1 Blocks PD-L1 Endocytosis and Improves the Response of Melanoma Cells to Immune Checkpoint BlockadeJournal of Investigative DermatologyVol. 141Issue 11PreviewImmune checkpoint molecules, especially PD-1 and its ligand PD-L1, act as a major mechanism of cancer immune evasion. Although anti–PD-1/PD-L1 monotherapy increases therapeutic efficacy in melanoma treatment, only a subset of patients exhibits long-term tumor remission, and the underlying mechanism of resistance to PD-1/PD-L1 inhibitors remains unclear. In this study, we demonstrated that cell surface retention of PD-L1 is inversely correlated with PAI-1 expression in vitro, in vivo, and in clinical specimens. Full-Text PDF" @default.
• W3205018834 created "2021-10-25" @default.
• W3205018834 creator A5008440351 @default.
• W3205018834 creator A5017879151 @default.
• W3205018834 creator A5054767907 @default.
• W3205018834 creator A5066829766 @default.
• W3205018834 creator A5076836970 @default.
• W3205018834 date "2021-11-01" @default.
• W3205018834 modified "2023-09-26" @default.
• W3205018834 title "A Possible Role for PAI-1 Blockade in Melanoma Immunotherapy" @default.
• W3205018834 cites W1619700982 @default.
• W3205018834 cites W1983376590 @default.
• W3205018834 cites W2071770551 @default.
• W3205018834 cites W2103971714 @default.
• W3205018834 cites W2136859769 @default.
• W3205018834 cites W2164745800 @default.
• W3205018834 cites W2607506177 @default.
• W3205018834 cites W2787095966 @default.
• W3205018834 cites W3010469101 @default.
• W3205018834 cites W3163174031 @default.
• W3205018834 doi "https://doi.org/10.1016/j.jid.2021.05.004" @default.
• W3205018834 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34688409" @default.
• W3205018834 hasPublicationYear "2021" @default.
• W3205018834 type Work @default.
• W3205018834 sameAs 3205018834 @default.
• W3205018834 citedByCount "3" @default.
• W3205018834 countsByYear W32050188342022 @default.
• W3205018834 countsByYear W32050188342023 @default.
• W3205018834 crossrefType "journal-article" @default.
• W3205018834 hasAuthorship W3205018834A5008440351 @default.
• W3205018834 hasAuthorship W3205018834A5017879151 @default.
• W3205018834 hasAuthorship W3205018834A5054767907 @default.
• W3205018834 hasAuthorship W3205018834A5066829766 @default.
• W3205018834 hasAuthorship W3205018834A5076836970 @default.
• W3205018834 hasBestOaLocation W32050188341 @default.
• W3205018834 hasConcept C126322002 @default.
• W3205018834 hasConcept C143998085 @default.
• W3205018834 hasConcept C170493617 @default.
• W3205018834 hasConcept C203014093 @default.
• W3205018834 hasConcept C2777658100 @default.
• W3205018834 hasConcept C2777701055 @default.
• W3205018834 hasConcept C2778468042 @default.
• W3205018834 hasConcept C502942594 @default.
• W3205018834 hasConcept C71924100 @default.
• W3205018834 hasConcept C8891405 @default.
• W3205018834 hasConceptScore W3205018834C126322002 @default.
• W3205018834 hasConceptScore W3205018834C143998085 @default.
• W3205018834 hasConceptScore W3205018834C170493617 @default.
• W3205018834 hasConceptScore W3205018834C203014093 @default.
• W3205018834 hasConceptScore W3205018834C2777658100 @default.
• W3205018834 hasConceptScore W3205018834C2777701055 @default.
• W3205018834 hasConceptScore W3205018834C2778468042 @default.
• W3205018834 hasConceptScore W3205018834C502942594 @default.
• W3205018834 hasConceptScore W3205018834C71924100 @default.
• W3205018834 hasConceptScore W3205018834C8891405 @default.
• W3205018834 hasIssue "11" @default.
• W3205018834 hasLocation W32050188341 @default.
• W3205018834 hasLocation W32050188342 @default.
• W3205018834 hasOpenAccess W3205018834 @default.
• W3205018834 hasPrimaryLocation W32050188341 @default.
• W3205018834 hasRelatedWork W2127132608 @default.
• W3205018834 hasRelatedWork W2184588837 @default.
• W3205018834 hasRelatedWork W2890817948 @default.
• W3205018834 hasRelatedWork W2903263827 @default.
• W3205018834 hasRelatedWork W3041158077 @default.
• W3205018834 hasRelatedWork W3215392064 @default.
• W3205018834 hasRelatedWork W4224244795 @default.
• W3205018834 hasRelatedWork W4307607145 @default.
• W3205018834 hasRelatedWork W4312075079 @default.
• W3205018834 hasRelatedWork W4377028999 @default.
• W3205018834 hasVolume "141" @default.
• W3205018834 isParatext "false" @default.
• W3205018834 isRetracted "false" @default.
• W3205018834 magId "3205018834" @default.
• W3205018834 workType "article" @default.